Cycle Computing, providing proven, secure and flexible high performance computing (HPC) and open source solutions in the cloud, today announced that the increasing enterprise demand for HPC and cloud computing is fueling its rapid expansion across industries. Cycle helps cutting-edge companies across market segments, including Eli Lilly, Pfizer and Varian Inc. in the pharmaceutical and life sciences space, to create their own supercomputers for unparalleled freedom and flexibility, faster time-to-market, increased productivity and reduced IT spend.

Running calculations quickly, easily and securely is a growing challenge for companies in compute-intensive industries.

CIO of the CIA Jill Singer Gives Highly Anticipated Talk during the 4th International Cloud Computing Expo Held Nov 2-4, 2009 in Santa Clara, CA

With some computations taking weeks to complete, these organizations often deal with significant delays in time to market and increased costs that impact the bottom line. Rather than adding more expensive infrastructure, forward-thinking enterprises have turned to the cloud. In fact, according to Gartner Inc.'s "Top 10 Strategic Technology Areas for 2010" report, cloud computing is first on the list for enterprise adoption in the year ahead.

Cycle enables organizations to leverage open source technologies to quickly and cost-effectively scale compute power in the cloud. CycleCloud provides fully secure, production-quality HPC clusters in the cloud that complement traditional virtualized environments. CycleCloud helps companies quickly create a cluster to get their applications up and running on hundreds of processors within hours. Once done, they can simply be shut down -- providing unprecedented efficiency and cost savings.

"Cycle gives us the ability to run our simulations securely, quickly and cost effectively," said Dr. Ramy Farid, president, Schrödinger, a scientific leader in developing state-of-the-art chemical simulation software. "Cycle has provided us with a highly robust solution for performing computations on the cloud, significantly reducing the demands on our in-house compute resources."

Specifically with the pharmaceutical and life sciences industry, Cycle's comprehensive HPC and cloud solutions portfolio continues to attract early adopters in the space -- empowering researchers to quickly, securely and inexpensively perform large-scale, critical calculations for drug discovery, clinical trials, risk analysis, design simulations, sequence analysis and more. For example, Pfizer has used Cycle Computing's CycleCloud services for molecular modeling, Varian Inc. to further design simulations and Eli Lilly for genome applications.

"Despite tightening IT budgets, enterprises are demanding stronger application agility and faster time to market -- and we've seen a great demand for our products and services because of this," said Jason Stowe, CEO, Cycle Computing. "The pharmaceutical and life sciences industry is one of our fastest growing market segments because it is turning toward the cloud to deal with its tremendous compute requirements. Cycle designed its solutions especially for these types of compute-intensive industries -- to create secure compute clusters that scale on the cloud, saving money and speeding time to results."